Sudeep Pharma IPO opens November 21: Check price band, dates, financials

Sudeep Pharma’s ₹895-crore IPO opens on November 21 with a price band of ₹563–₹593. Know the key dates, financial performance, risks, and strengths before you invest.

Sudeep Pharma IPO will open on Friday, November 21.

Sudeep Pharma’s initial public offering (IPO) will open on Friday, November 21, and close on November 25. The issue is being launched as a book-built IPO, with the company aiming to raise about Rs 895 crore. This includes a fresh issue worth Rs 95 crore and an offer for sale (OFS) of 1,34,90,726 equity shares with a face value of Rs 1 each.

The IPO has been priced in the range of Rs 563 to Rs 593 per share. Of the total offering, 50% has been reserved for qualified institutional buyers (QIBs), 35% for retail investors, and 15% for high-net-worth individuals. Sudeep Pharma’s shares will be listed on the bourses, both BSE and NSE, on November 28 while the allotment is scheduled for November 26.

For FY25, Sudeep Pharma reported revenue of Rs 511.33 crore, an increase from Rs 465.38 crore in FY24. Net profit also rose slightly to Rs 138.69 crore in FY25 from Rs 133.15 crore in the previous fiscal. Based on these financials, the IPO appears suited for investors with a long-term view.

Story continues below this ad

Also Read | Excelsoft Technologies IPO today: GMP at 12.5% ahead of opening; check price band and other details

Sudeep Pharma, which manufactures pharmaceutical excipients (products which are not the drug itself but aid the delivery medium like preservatives, colouring agents, etc) will launch its first public issue on Friday, November 21, 2025. The offer includes a fresh issue of 1.6 million shares totalling Rs 95 crore, along with an OFS of up to 13.5 million shares worth Rs 800 crore.

The IPO price band remains Rs 563-Rs 593 per share, and investors can apply for a minimum of 25 shares per lot. Subscriptions will be accepted until Tuesday, November 25, 2025. The company’s stock is expected to debut on the exchanges on Friday, November 28, 2025.

MUFG Intime India has been appointed registrar to the issue, while ICICI Securities and IIFL Capital Services are acting as the book-running lead managers.

According to the Red Herring Prospectus (RHP) filed with the SEBI, Sudeep Pharma plans to allocate Rs 75.81 crore from the fresh issue towards acquiring machinery for its production line at the Nandesari facility. The rest of the proceeds will be used for general corporate purposes.